|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
||
|
|
The
|
Director
|
Votes Cast For
|
Votes Withheld
|
Broker Non-Votes
|
|||
Joshua R. Disbrow
|
2,111,846
|
596,291
|
1,329,025
|
|||
John A. Donofrio, Jr.
|
2,068,029
|
640,108
|
1,329,025
|
|||
Carl C. Dockery
|
2,055,295
|
652,842
|
1,329,025
|
|||
Abhinav “Abi” Jain
|
2,074,470
|
633,667
|
1,329,025
|
|||
Vivian H. Liu
|
2,067,904
|
640,233
|
1,329,025
|
Votes Cast For
|
Votes Cast Against
|
Votes Cast Abstain
|
Broker Non-Votes
|
|||
3,290,868
|
683,165
|
63,129
|
─
|
Votes Cast For
|
Votes Cast Against
|
Votes Cast Abstain
|
Broker Non-Votes
|
|||
1,978,765
|
659,394
|
69,978
|
1,329,025
|
AYTU BIOPHARMA, INC.
|
||
Date: June 26, 2024
|
By:
|
/s/ Mark K. Oki
|
Mark K. Oki
|
||
Chief Financial Officer
|
Document And Entity Information |
Jun. 26, 2024 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | AYTU BIOPHARMA, INC. |
Document, Type | 8-K |
Document, Period End Date | Jun. 26, 2024 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-38247 |
Entity, Tax Identification Number | 47-0883144 |
Entity, Address, Address Line One | 7900 E. Union Avenue |
Entity, Address, Address Line Two | Suite 920 |
Entity, Address, City or Town | Denver |
Entity, Address, State or Province | CO |
Entity, Address, Postal Zip Code | 80237 |
City Area Code | 720 |
Local Phone Number | 437-6580 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | AYTU |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0001385818 |
@[F48PL'S%PW+&GL;#);N#2\?W.VX7&]/KBN_Z++X@BF#>9]4)*>SD M230.)"XYN'8<I?=GY'ZR+K6RT9EQSGG/-2A^Y]AP, M\ZA\N/\- %P49O_%JV:NS,EW[@(&X>[ M173RA+'5-<(]KTA4;#.9:1J3/WAZTE%:)'W'ZV"3V*UK@XN;>S&$ :SQ3J/@ M @,\N>KRX.*F_EF&$)/91@K,WUI$NIW!9;_GHT1U47!QW_ZBN-9,0&"2)!=[ M<\L:J7"A%8TSU"CJ(N#B!CZ7,0^YYF)-'B"_%:=Q(P^NTLI3UP 7=^R98I%>G^(:;K1A1 6QE O%DN7/ZZZ>S;"=I=67=A['-H N6/O.-%Q[I#)6,>=56R=M8SDK M6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9) ML;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2 MVSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK= M5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>6 M5Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEU MXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z M6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$// M\A=>BD[E\ZI[J,NXZBQ_AOMHD \%G'!QR>(W?# M$T %^@2O&+(=/EB>N$_N MG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"= MXI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C% M^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_ M5U/\!%!+ P04 " "1A-I8EXJ[', 3 @ "P %]R96QS+RYR96QS MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2 MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N M&6:WO606IW.D5XA -/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E MC'%BM/XU@LD/['X 4$L#!!0 ( )&$VE@ZJJ+G0 $ #P" / >&PO M=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@2 0SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;B(S5'WC3B?PT M9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D0XMAU]&(B^S" M1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB[H-5CX$E)+4* M Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#V# :;7-Y-; M2>C@W(-@[^&5C!W-CQ]W]P-02P,$% @ D83:6"0>FZ*M ^ $ !H M !X;"]? +7_OR4Z?:!1W;J"V\R1&:P;*9,OL M[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C] MLCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP M3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( )&$VEAED'F2&0$ ,\# M 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@ M"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0" M50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M- M\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[ M0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TF MGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D &PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( )&$VEAP7IO8700 $(1 8 " @0T( M !X;"]W;W)K &PO &PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " "1A-I899!YDAD! #/ P $P M@ &W$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !% " ! end
R(R ^#Z?*1X\;, \$*L0E0:*S:@I1Q9X60<2<+1A0$8&)7P1&W9AYA-\YH
M>7=LR72507B;&G STXE.PRC#%KR![,5>);,"%N/P_8A1]_#-+^]#'GKL$'OH
M1K/ZO[5O>3#V[PNZ"?K\AV&03\QG 0V92_I3TM/2= 321"Y$$%*/&*12L"MJ
M!E)IE,U&J4@N3HEA@'L9LY 2A,=@_T3\ZL->2_@A\T.C!]JP1QQ]]6$O9#=A
M0?F9PN'[@H;P?5^X4R+#J0>".X">AN3_QQK$,B?A 5$W!G3,O6F#_/Y/),*#
M'A\S2<[8->F*,?7US0,RH2YZO08QN4_,O,7] P+'-U%9;(U@UY;5+D
MEJVM%U)8V/''#A-?S57"G$ZF&=4:Y4<=BO5^*=2>&PIPOKB04E2C *>0F;.L
M@%#Z6*_Q.?&/\T=Z/#\*\O]1N.J]"XWNPH/3FU/;W1(NTZMG<)FH01X@4%P5
M@